Iris Isufi, MD
Associate Professor of Medicine (Hematology)DownloadHi-Res Photo
Cards
Additional Titles
Co-Director Adult CAR T-Cell Therapy Program, Hematology
Co-Leader, Cellular Therapy Clinical Research Team, Yale Cancer Center
Co-Chair, Cellular Therapy (CT)-SAFE Committee, Yale Cancer Center
Contact Info
About
Copy Link
Titles
Associate Professor of Medicine (Hematology)
Co-Director Adult CAR T-Cell Therapy Program, Hematology; Co-Leader, Cellular Therapy Clinical Research Team, Yale Cancer Center; Co-Chair, Cellular Therapy (CT)-SAFE Committee, Yale Cancer Center
Appointments
Medical Oncology and Hematology
Associate Professor on TermPrimary
Other Departments & Organizations
- Developmental Therapeutics
- Hematology
- Internal Medicine
- Leukemia & Lymphoma Program
- Medical Oncology and Hematology
- Office for CE in Medicine
- Yale Cancer Center
- Yale Ventures
- YCC Collaborative Excellence
Education & Training
- Fellowship
- Yale University School of Medicine (2011)
- Residency
- Albert Einstein College of Medicine/Montefiore Medical Center (2007)
- MD
- State University of New York at Stony Brook (2004)
- BA
- The College of Saint Rose, Albany, NY, 2000, Biology (2000)
Research
Copy Link
Overview
Dr. Isufi's clinical work has been in the area of hematologic malignancies and autologous and allogeneic stem cell transplantation for these conditions. As part of the lymphoid malignancy and transplant teams, she developed a strong clinical interest in aggressive lymphomas. She has focused her efforts in treating patients with aggressive lymphomas as part of clinical trials and consolidating their response to treatment with either autologous or allogeneic transplant based on specifics of their disease. She has a research interest in early drug development in lymphoma, and has served as local PI for a variety of industry- and cooperative-group-sponsored lymphoma trials, including phase 1 trials.
Medical Research Interests
Bone Marrow Transplantation; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Graft vs Host Disease; Lymphoma; Transplantation Conditioning
Research at a Glance
Yale Co-Authors
Frequent collaborators of Iris Isufi's published research.
Publications Timeline
A big-picture view of Iris Isufi's research output by year.
Research Interests
Research topics Iris Isufi is interested in exploring.
Stuart Seropian, MD
Francine Foss, MD
Lohith Gowda, MD, MRCP
Scott Huntington, MD, MPH, MSc
Shalin Kothari, MD
Tarsheen Sethi, MD, MSc
53Publications
512Citations
Graft vs Host Disease
Transplantation Conditioning
Lymphoma
Publications
2025
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL
Cahill K, Godfrey J, Nabhan C, Kline J, Riedell P, Cohen K, Narula S, Karrison T, Robertson J, Karmali R, Venugopal P, Kim S, Rapoport A, Lee S, Law J, Fishkin P, Isufi I, Velasco M, Kaminer L, Smith S. A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL. Blood Advances 2025, 9: 5665-5675. PMID: 40720747, DOI: 10.1182/bloodadvances.2025017092.Peer-Reviewed Original ResearchCitationsConceptsDiffuse large B-cell lymphomaDA-EPOCH-RProgression-free survivalDose-adjusted EPOCH-REPOCH-RResponse rateEfficacy criteriaRandomized trialsMulticenter phase 1/2 studyLarge B-cell lymphomaBenefit of lenalidomidePhase 1/2 studyTrial of lenalidomideMedian Follow-UpB-cell lymphomaMyc-driven lymphomasFifty-five patientsDeregulation of MYCR-CHOPBCL2 rearrangementNeutropenic feverOverall survivalPrimary malignancyStage III/IVInferior outcomesPrognostic impact of cytogenetic abnormalities in aggressive T-cell lymphomas: Defining high-risk subgroups through conventional karyotyping.
Kiwan A, Diadamo A, Wen J, Kewan T, Siddon A, Kothari S, Isufi I, Seropian S, Huntington S, Montanari F, Xu M, Li P, Girardi M, Sethi T, Foss F. Prognostic impact of cytogenetic abnormalities in aggressive T-cell lymphomas: Defining high-risk subgroups through conventional karyotyping. Blood 2025, 146: 1759-1759. DOI: 10.1182/blood-2025-1759.Peer-Reviewed Original ResearchConceptsT-cell lymphomaMature T-cell lymphomasAggressive T-cell lymphomaUnivariate Cox proportional hazardsMonosomy 9Overall survivalPeripheral bloodMonosomy 5Nodal PTCLBone marrowHigh-risk subgroupsPrognostic significancePlatelet countCox proportional hazardsCytogenetic abnormalitiesPrognostic impactComplex karyotypeT cellsMarker chromosomesPrognostic impact of cytogenetic abnormalitiesPredictor of poor OSImpact of cytogenetic abnormalitiesMultivariate CPH modelChromosomal lesionsPresence of marker chromosomesConcurrent TP53 loss-of-function and epigenetic modifier mutations as a potential predictor of chemoimmunotherapy failure in DLBCL & hgbl
Ravishankar A, Isufi I, Huntington S, Seropian S, Foss F, Sethi T, Kothari S. Concurrent TP53 loss-of-function and epigenetic modifier mutations as a potential predictor of chemoimmunotherapy failure in DLBCL & hgbl. Blood 2025, 146: 7071-7071. DOI: 10.1182/blood-2025-7071.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaHigh-grade B-cell lymphomaCell of originChimeric antigen receptorCAR-T therapyComprehensive genomic profilingB-cell lymphomaFirst-line therapyTP53 mutationsCAR-TClinicopathological variablesAssociated with failureLoss-of-functionIPI scoreCR patientsPerformance statusRearrangement statusResponse to first-line therapyGenomic profilingAllogeneic stem cell transplantationLarge B-cell lymphomaMarker of poor prognosisAnthracycline-based chemoimmunotherapyDiagnostic tumor samplesStatus of MYCAberrant circulating CD4+ CD26- T-cells in T-cell rich B-cell lymphomas: Diagnostic pitfall or biomarker?
Ravishankar A, Chen P, Xu M, Braddock D, Siddon A, Isufi I, Huntington S, Seropian S, Foss F, Kothari S, Sethi T. Aberrant circulating CD4+ CD26- T-cells in T-cell rich B-cell lymphomas: Diagnostic pitfall or biomarker? Blood 2025, 146: 7182. DOI: 10.1182/blood-2025-7182.Peer-Reviewed Original ResearchConceptsNodular lymphocyte-predominant Hodgkin lymphomaT-cell/histiocyte-rich large B-cell lymphomaB-cell lymphomaT cell populationsT-cell-rich B-cell lymphomaT-cell clonalityT cellsPeripheral bloodHodgkin lymphomaYounger patientsDiagnostic pitfallsB cellsSensitivity to PD-1 blockadeT-cell non-Hodgkin's lymphomaCD4+ T cell subsetsAberrant T-cell populationLymphocyte-predominant Hodgkin lymphomaT-cell-rich backgroundAggressive B-cell lymphomasLarge B-cell lymphomaRepertoire analysisAbnormal T-cell populationCohort of young patientsCD26- T cellsDiagnostic lymph nodesPentostatin/TBI conditioning for allogeneic transplantation in T-cell lymphomas
Taborda C, Isufi I, Sethi T, Bar N, Gowda L, Wilson L, Girardi M, Roberts K, Seropian S, Foss F. Pentostatin/TBI conditioning for allogeneic transplantation in T-cell lymphomas. Blood 2025, 146: 2433. DOI: 10.1182/blood-2025-2433.Peer-Reviewed Original ResearchConceptsT-cell lymphomaTotal body irradiationGraft-versus-lymphomaOverall survivalComplete remissionRare subtypeT cellsConditioning regimensMedian OSChronic GVHDAllogeneic transplantationRemission statusCumulative incidenceCumulative incidence of grade II–IV acute GVHDIncidence of grade II-IV acute GVHDProspective evaluationCalcineurin inhibitor-based GVHD prophylaxisGrade II-IV acute GVHDLow-dose total body irradiationDonor typeReduced-intensity conditioning regimensAllogeneic stem cell transplantationAnaplastic large cell lymphomaPeripheral T-cell lymphomaAggressive T-cell lymphomaOutpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry
Patel K, Lunning M, Sdrimas K, Battiwalla M, Rao U, Lin Y, Ibrahimi S, Crombie J, Ahmed S, Isufi I, Frigault M, Bernasconi D, Roy D, Pasquini M, Hunter B. Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry. Blood 2025, 146: 5482-5482. DOI: 10.1182/blood-2025-5482.Peer-Reviewed Original ResearchConceptsLarge B-cell lymphomaImmune effector cell-associated neurotoxicity syndromeR/R large B-cell lymphomaDuration of responseB-cell lymphomaLiso-celNonrelapse mortalityOP groupStandard of careSafety profileIP groupOP settingsCD19-directed CAR-T cell productsFollow-upHigh-grade B-cell lymphomaDuration of response rateCAR-T cell productsObservational studyExtranodal involved sitesGrade 2 CRSNonrelapse mortality rateSecondary CNS involvementClinically significant infectionsB-cell malignanciesClinically meaningful efficacyCRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting
Hunter B, Lunning M, Shadman M, Ahmed S, Abramson J, Perales M, Ahmed N, Mirza A, Isufi I, Frigault M, Crombie J, Miklos D, Vasconcelos A, Crotta A, Bernasconi D, Roy D, Bleickardt E, Pasquini M, Kamdar M. CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting. Transplantation And Cellular Therapy 2025 PMID: 41235976, DOI: 10.1016/j.jtct.2025.10.024.Peer-Reviewed Original ResearchAltmetricConceptsCytokine release syndromeMedian time to resolutionTime to resolutionChimeric antigen receptorClinical trialsLiso-celB cellsCenter for International Blood and Marrow Transplant Research (CIBMTR) registryB-cell lymphomaReal-world settingsLisocabtagene maraleucelTherapy infusionT cellsAntigen receptorInfusionPatientsTrialsTreatment accessPatient safety monitoringDaysOutcomesLymphomaSyndromeReceptorsClinicWeekly dosing schedule of brentuximab vedotin is well tolerated in mycosis fungoides/Sézary syndrome
Lee M, Schiffer M, Isufi I, Huntington S, Xu M, Sethi T, Kothari S, Girardi M, Foss F. Weekly dosing schedule of brentuximab vedotin is well tolerated in mycosis fungoides/Sézary syndrome. British Journal Of Haematology 2025, 207: 2140-2142. PMID: 40968584, DOI: 10.1111/bjh.70147.Peer-Reviewed Original ResearchAltmetricCT-305: Optimizing Post-Chimeric Antigen Receptor (CAR) T-Cell Monitoring: Evidence Across Lisocabtagene Maraleucel (liso-cel) Pivotal Clinical Trials and Real-World Experience
Kamdar M, Shadman M, Ahmed S, Abramson J, Perales M, Ahmed N, Mirza A, Isufi I, Frigault M, Crombie J, Miklos D, Vasconcelos A, Crotta A, Bernasconi D, Roy D, Bleickardt E, Pasquini M, Hunter B, Lunning M. CT-305: Optimizing Post-Chimeric Antigen Receptor (CAR) T-Cell Monitoring: Evidence Across Lisocabtagene Maraleucel (liso-cel) Pivotal Clinical Trials and Real-World Experience. Clinical Lymphoma Myeloma & Leukemia 2025, 25: s1010-s1011. DOI: 10.1016/s2152-2650(25)02770-3.Peer-Reviewed Original ResearchCitationsConceptsImmune effector cell-associated neurotoxicity syndromeCytokine release syndromeCenter for International Blood and Marrow Transplant ResearchStandard-of-careClinical trialsB-cell non-Hodgkin lymphomaCAR-T cell therapyStandard-of-care settingsT-cell therapyNon-Hodgkin's lymphomaMarrow Transplant ResearchLiso-celLisocabtagene maraleucelPivotal trialsAntigen receptorNeurotoxicity syndromeB cellsInfusionPatientsTransplantation researchInformed consentRegistry dataLBCLLow gradeWeeksPOSTER: CT-305 Optimizing Post-Chimeric Antigen Receptor (CAR) T-Cell Monitoring: Evidence Across Lisocabtagene Maraleucel (liso-cel) Pivotal Clinical Trials and Real-World Experience
Kamdar M, Shadman M, Ahmed S, Abramson J, Perales M, Ahmed N, Mirza A, Isufi I, Frigault M, Crombie J, Miklos D, Vasconcelos A, Crotta A, Bernasconi D, Roy D, Bleickardt E, Pasquini M, Hunter B, Lunning M. POSTER: CT-305 Optimizing Post-Chimeric Antigen Receptor (CAR) T-Cell Monitoring: Evidence Across Lisocabtagene Maraleucel (liso-cel) Pivotal Clinical Trials and Real-World Experience. Clinical Lymphoma Myeloma & Leukemia 2025, 25: s318. DOI: 10.1016/s2152-2650(25)01398-9.Peer-Reviewed Original Research
Clinical Trials
Current Trials
Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
HIC ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028Recruiting ParticipantsPhase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma
HIC ID2000032539RolePrincipal InvestigatorPrimary Completion Date05/19/2029Recruiting ParticipantsA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
HIC ID2000030190RoleSub InvestigatorPrimary Completion Date06/02/2026Recruiting ParticipantsNovel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
HIC ID2000028918RoleSub InvestigatorPrimary Completion Date01/30/2026Recruiting ParticipantsA Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
HIC ID2000028478RolePrincipal InvestigatorPrimary Completion Date07/30/2023Recruiting Participants
Academic Achievements & Community Involvement
Copy Link
Honors
honor ASCO/AACR Methods in Clinical Cancer Research Workshop Fellow, Vail, CO
08/01/2008National AwardAACRDetailsUnited Stateshonor Outstanding House Officer in Internal Medicine Award
10/01/2007Other AwardAlbert Einstein College of Medicine/Montefiore Medical CenterDetailsUnited Stateshonor The Kijeon Yoo Award for Determination in Pursuit of a Medical Education
10/01/2004Other AwardStony Brook University School of MedicineDetailsUnited Stateshonor Medical School Merit-Based Scholarship
10/01/2004Other AwardStony Brook University School of MedicineDetailsUnited States
News & Links
Copy Link
News
- March 31, 2025
Yale’s Post ASH Review: Highlights from the 2024 American Society of Hematology Annual Meeting
- November 26, 2024
Yale Cancer Center to Highlight Breakthroughs in Blood Cancers and Disorders at World’s Largest Hematology Meeting
- July 30, 2024
Smilow Cancer Hospital Cellular Therapies Program
- November 08, 2023
Smilow Shares with Primary Care: Lymphadenopathy and Diagnosis
Get In Touch
Copy Link